The Dental Status of Patients Taking Common Biologic Agents: A Single-Center Cross-Sectional Study.

IF 2.9 3区医学 Q1 DENTISTRY, ORAL SURGERY & MEDICINE

Oral diseases Pub Date : 2025-03-17 DOI:10.1111/odi.15311

Shivani Shah, Nila Veerabagu, Nana A A Essel, Neda Mahjour, Katherine France

{"title":"The Dental Status of Patients Taking Common Biologic Agents: A Single-Center Cross-Sectional Study.","authors":"Shivani Shah, Nila Veerabagu, Nana A A Essel, Neda Mahjour, Katherine France","doi":"10.1111/odi.15311","DOIUrl":null,"url":null,"abstract":"Objectives: Despite expanding use and medical applications, little is known about the impact of biologic agents (BAs) on dental treatment. The aim of this study was to investigate the dental status of patients on common classes of BAs to understand treatment needs and use in this population.Methods: A retrospective cross-sectional study was conducted on patients treated with the most common classes of BA (tumor necrosis factor-alpha [TNF-α] inhibitors, interleukin (IL) inhibitors, and lymphocyte modulators) from 1/7/2017 to 1/7/2022. Data on demographic factors, BA treatment, medical conditions including indication, restorative and periodontal treatments, and decayed, missing, and filled tooth index (DMFT) were compared descriptively.Results: The study identified 247 patients treated with 24 different BAs. Restorative and periodontal treatment was completed on 60.3% and 72.9% of patients, respectively. The DMFT scores were higher in the study cohort compared to the average US adult population. The analysis revealed an upward trend in both periodontal and restorative treatments.Conclusions: This study provides the first comprehensive characterization of the oral health status and treatment needs of patients taking BAs. The findings suggest a higher dental treatment burden in this population, particularly regarding restorative care in this population, a finding that may be confirmed or expanded in future evaluations.","PeriodicalId":19615,"journal":{"name":"Oral diseases","volume":" ","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oral diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/odi.15311","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DENTISTRY, ORAL SURGERY & MEDICINE","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: Despite expanding use and medical applications, little is known about the impact of biologic agents (BAs) on dental treatment. The aim of this study was to investigate the dental status of patients on common classes of BAs to understand treatment needs and use in this population.

Methods: A retrospective cross-sectional study was conducted on patients treated with the most common classes of BA (tumor necrosis factor-alpha [TNF-α] inhibitors, interleukin (IL) inhibitors, and lymphocyte modulators) from 1/7/2017 to 1/7/2022. Data on demographic factors, BA treatment, medical conditions including indication, restorative and periodontal treatments, and decayed, missing, and filled tooth index (DMFT) were compared descriptively.

Results: The study identified 247 patients treated with 24 different BAs. Restorative and periodontal treatment was completed on 60.3% and 72.9% of patients, respectively. The DMFT scores were higher in the study cohort compared to the average US adult population. The analysis revealed an upward trend in both periodontal and restorative treatments.

Conclusions: This study provides the first comprehensive characterization of the oral health status and treatment needs of patients taking BAs. The findings suggest a higher dental treatment burden in this population, particularly regarding restorative care in this population, a finding that may be confirmed or expanded in future evaluations.

查看原文本刊更多论文

服用常用生物制剂患者的牙齿状况：一项单中心横断面研究。

目的：尽管生物制剂的使用和医学应用越来越广泛，但人们对生物制剂（BAs）在牙科治疗中的影响知之甚少。本研究的目的是调查常见类别的牙科患者的牙齿状况，以了解该人群的治疗需求和使用情况。方法：回顾性横断面研究对2017年7月1日至2022年7月1日期间最常见的BA（肿瘤坏死因子-α抑制剂、白细胞介素（IL）抑制剂和淋巴细胞调节剂）治疗的患者进行了研究。统计因素、BA治疗、医疗条件（包括指征）、修复和牙周治疗、蛀牙、缺牙和补牙指数（DMFT）的数据进行描述性比较。结果：该研究确定了247例接受24种不同BAs治疗的患者。修复治疗和牙周治疗完成率分别为60.3%和72.9%。与美国成年人的平均水平相比，研究队列中的DMFT得分更高。分析显示，牙周治疗和修复治疗均呈上升趋势。结论：本研究首次全面表征了服用ba患者的口腔健康状况和治疗需求。研究结果表明，这一人群的牙科治疗负担较高，特别是在这一人群的修复护理方面，这一发现可能会在未来的评估中得到证实或扩大。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Oral diseases 医学-牙科与口腔外科

CiteScore

7.60

自引率

5.30%

发文量

325

审稿时长

4-8 weeks

期刊介绍： Oral Diseases is a multidisciplinary and international journal with a focus on head and neck disorders, edited by leaders in the field, Professor Giovanni Lodi (Editor-in-Chief, Milan, Italy), Professor Stefano Petti (Deputy Editor, Rome, Italy) and Associate Professor Gulshan Sunavala-Dossabhoy (Deputy Editor, Shreveport, LA, USA). The journal is pre-eminent in oral medicine. Oral Diseases specifically strives to link often-isolated areas of dentistry and medicine through broad-based scholarship that includes well-designed and controlled clinical research, analytical epidemiology, and the translation of basic science in pre-clinical studies. The journal typically publishes articles relevant to many related medical specialties including especially dermatology, gastroenterology, hematology, immunology, infectious diseases, neuropsychiatry, oncology and otolaryngology. The essential requirement is that all submitted research is hypothesis-driven, with significant positive and negative results both welcomed. Equal publication emphasis is placed on etiology, pathogenesis, diagnosis, prevention and treatment.